Astrana Health (NASDAQ:ASTH) Given New $56.00 Price Target at Stifel Nicolaus

Astrana Health (NASDAQ:ASTHFree Report) had its price objective lowered by Stifel Nicolaus from $70.00 to $56.00 in a research note released on Thursday,Benzinga reports. The brokerage currently has a buy rating on the stock.

A number of other equities research analysts also recently weighed in on the company. Macquarie upgraded Astrana Health to a “hold” rating in a research report on Monday, December 16th. Robert W. Baird boosted their price objective on Astrana Health from $67.00 to $86.00 and gave the stock an “outperform” rating in a report on Wednesday, November 13th. Finally, Truist Financial cut their target price on shares of Astrana Health from $59.00 to $50.00 and set a “buy” rating on the stock in a research report on Monday, January 13th. Two equities research analysts have rated the stock with a hold rating, six have assigned a buy rating and one has given a strong buy rating to the company’s stock. According to data from MarketBeat, Astrana Health has a consensus rating of “Moderate Buy” and an average price target of $63.00.

View Our Latest Report on Astrana Health

Astrana Health Stock Performance

ASTH stock opened at $37.39 on Thursday. The company has a 50 day moving average price of $35.10 and a 200 day moving average price of $45.07. Astrana Health has a fifty-two week low of $29.08 and a fifty-two week high of $63.20. The company has a debt-to-equity ratio of 0.60, a current ratio of 1.91 and a quick ratio of 1.91. The stock has a market capitalization of $2.10 billion, a PE ratio of 28.76, a price-to-earnings-growth ratio of 1.50 and a beta of 1.20.

Hedge Funds Weigh In On Astrana Health

Hedge funds have recently added to or reduced their stakes in the stock. PharVision Advisers LLC acquired a new position in shares of Astrana Health during the 4th quarter worth about $211,000. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC boosted its stake in Astrana Health by 15.6% during the 4th quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 104,658 shares of the company’s stock worth $3,300,000 after acquiring an additional 14,138 shares during the last quarter. Squarepoint Ops LLC acquired a new position in Astrana Health during the fourth quarter valued at approximately $1,208,000. Two Sigma Investments LP bought a new stake in Astrana Health in the fourth quarter valued at approximately $466,000. Finally, Sherbrooke Park Advisers LLC acquired a new stake in Astrana Health in the fourth quarter worth $494,000. Institutional investors and hedge funds own 52.77% of the company’s stock.

About Astrana Health

(Get Free Report)

Astrana Health, Inc, Inc, a physician-centric technology-powered healthcare management company, provides medical care services in the United States. It operates through three segments: Care Partners, Care Delivery, and Care Enablement. The company is leveraging its proprietary population health management and healthcare delivery platform, operates an integrated, value-based healthcare model which empowers the providers in its network to deliver care to its patients.

See Also

Analyst Recommendations for Astrana Health (NASDAQ:ASTH)

Receive News & Ratings for Astrana Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Astrana Health and related companies with MarketBeat.com's FREE daily email newsletter.